Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Niraparib (Primary)
- Indications Ovarian cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRIMA
- Sponsors TESARO
- 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 25 Aug 2017 According to a TESARO media release, data from this study will be presented at the 2017 European Society for Medical Oncology (ESMO) annual meeting.
- 10 Jun 2017 Biomarkers information updated